Tim Campellone
Research Subjects
Tim Campellone has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Abhishek Pratap
Department of Biostatistics & Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, SGDP Centre, IoPPN, De Crespigny Park, Denmark Hill London, London, United Kingdom, 44 2078480473
3 shared publications - Brendan D. Hare
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
3 shared publications - Cornelia Dorner-Ciossek
Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
3 shared publications - Olya Besedina
Click Therapeutics Inc, New York, NY, United States
3 shared publications - Shaheen Emmanuel Lakhan
Bioscience, Global Neuroscience Initiative Foundation, Miami, USA
3 shared publications - Aaron Pavez
Woebot Health, San Francisco, CA, United States
2 shared publications
Latest Publications
- Open Access
- 26 September 2025
- Published by Springer Nature in Schizophrenia
- Vol. 11 (1) , 1-13
Feasibility of a digital therapeutic for experiential negative symptoms of schizophrenia: results from an exploratory study
Experiential negative symptoms (ENS) of schizophrenia, such as asociality, anhedonia, and avolition, are associated with poor outcomes, yet no FDA-approved pharmacotherapies currently exist specifically to target these symptoms. With the increasing use of smartphones, evidence-based digital interventions delivered by prescription digital therapeutics (DTx) may present an opportunity to address the unmet therapeutic need for ENS of schizophrenia. CT‑155/BI 3972080 (CT-155) is being developed as a smartphone-based prescription DTx for the treatment of ENS. A multicenter, 7-week, single-arm, open-label, exploratory study (NCT05486312) evaluated the engagement, adherence, potential effectiveness, acceptability, user experience, and safety of an abbreviated version of CT-155 (CT‑155 beta). Engagement and adherence with CT-155 beta were measured passively throughout the study using the study app. Change in ENS severity was assessed using the clinically administered clinical assessment interview for negative symptoms, motivation, and pleasure subscale (CAINS-MAP). Acceptability and user experience were assessed using the validated Mobile App Rating Scale (MARS) along with an episodic user experience survey, respectively. Fifty participants with a clinically confirmed schizophrenia diagnosis were enrolled; 80% were male, 58% were Black or African American, and the median (range) age was 53.5 (23–64) years. At baseline, participants' mean (SD) CAINS-MAP total score was 20.5 (8.3). Most participants (n = 43; 86%) completed the 7-week study. Participants readily engaged with CT-155 beta. Kaplan–Meier retention analysis showed that 84% of participants (N = 42/50) engaged with CT-155 beta (i.e., last app open) until the end of the study period. Daily app check-ins were completed on a median (IQR) of 43.0 (19–47) days of the 49 possible days (88%). The median (IQR) duration of engagement was 11.6 (8.1–16.1) min per session. Additionally, adherence with CT-155 was high, with participants completing a median of 18 (IQR 13–20) of the 21 therapeutic lessons available. After 7 weeks of CT-155 beta usage, the mean change in within-subject CAINS-MAP score was 3.6 points from baseline (95% CI 1.3, 5.8; p = 0.0026; baseline: 20.4 (8.6) Week 7: 16.8 (7.7)). Most participants (91%; n = 39/43) rated CT-155 beta functionality using MARS assessment as acceptable or higher, with an overall mean MARS functionality subscale score of 4.2 points out of 5 points, with 5 corresponding to “excellent” at Week 7. The end of study participant feedback survey showed that 95% (n = 42/44) of participants would recommend using CT-155 beta. No app-related adverse events nor severe adverse events leading to discontinuation of the study were reported. Overall, the study demonstrated the feasibility of CT-155 beta in participants with ENS of schizophrenia. Results from this feasibility study show the potential of evidence-based DTx approaches to address ENS of schizophrenia.
- 26 September 2025
- Published by Springer Nature in Schizophrenia
- Vol. 11 (1) , 1-13
Open AccessFeasibility of a digital therapeutic for experiential negative symptoms of schizophrenia: results from an exploratory study
Experiential negative symptoms (ENS) of schizophrenia, such as asociality, anhedonia, and avolition, are associated with poor outcomes, yet no FDA-approved pharmacotherapies currently exist specifically to target these symptoms. With the increasing use of smartphones, evidence-based digital interventions delivered by prescription digital therapeutics (DTx) may present an opportunity to address the unmet therapeutic need for ENS of schizophrenia. CT‑155/BI 3972080 (CT-155) is being developed as a smartphone-based prescription DTx for the treatment of ENS. A multicenter, 7-week, single-arm, open-label, exploratory study (NCT05486312) evaluated the engagement, adherence, potential effectiveness, acceptability, user experience, and safety of an abbreviated version of CT-155 (CT‑155 beta). Engagement and adherence with CT-155 beta were measured passively throughout the study using the study app. Change in ENS severity was assessed using the clinically administered clinical assessment interview for negative symptoms, motivation, and pleasure subscale (CAINS-MAP). Acceptability and user experience were assessed using the validated Mobile App Rating Scale (MARS) along with an episodic user experience survey, respectively. Fifty participants with a clinically confirmed schizophrenia diagnosis were enrolled; 80% were male, 58% were Black or African American, and the median (range) age was 53.5 (23–64) years. At baseline, participants' mean (SD) CAINS-MAP total score was 20.5 (8.3). Most participants (n = 43; 86%) completed the 7-week study. Participants readily engaged with CT-155 beta. Kaplan–Meier retention analysis showed that 84% of participants (N = 42/50) engaged with CT-155 beta (i.e., last app open) until the end of the study period. Daily app check-ins were completed on a median (IQR) of 43.0 (19–47) days of the 49 possible days (88%). The median (IQR) duration of engagement was 11.6 (8.1–16.1) min per session. Additionally, adherence with CT-155 was high, with participants completing a median of 18 (IQR 13–20) of the 21 therapeutic lessons available. After 7 weeks of CT-155 beta usage, the mean change in within-subject CAINS-MAP score was 3.6 points from baseline (95% CI 1.3, 5.8; p = 0.0026; baseline: 20.4 (8.6) Week 7: 16.8 (7.7)). Most participants (91%; n = 39/43) rated CT-155 beta functionality using MARS assessment as acceptable or higher, with an overall mean MARS functionality subscale score of 4.2 points out of 5 points, with 5 corresponding to “excellent” at Week 7. The end of study participant feedback survey showed that 95% (n = 42/44) of participants would recommend using CT-155 beta. No app-related adverse events nor severe adverse events leading to discontinuation of the study were reported. Overall, the study demonstrated the feasibility of CT-155 beta in participants with ENS of schizophrenia. Results from this feasibility study show the potential of evidence-based DTx approaches to address ENS of schizophrenia.
- Top Cited PapersOpen Access
- 23 May 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27 (1) , e67365
Safety and User Experience of a Generative Artificial Intelligence Digital Mental Health Intervention: Exploratory Randomized Controlled Trial
Background: General awareness and exposure to generative artificial intelligence (AI) have increased recently. This transformative technology has the potential to create a more dynamic and engaging user experience in digital mental health interventions (DMHIs). However, if not appropriately used and controlled, it can introduce risks to users that may result in harm and erode trust. At the time of conducting this trial, there had not been a rigorous evaluation of an approach to safely implementing generative AI in a DMHI. Objective: This study aims to explore the user relationship, experience, safety, and technical guardrails of a DMHI using generative AI compared with a rules-based intervention. Methods: We conducted a 2-week exploratory randomized controlled trial (RCT) with 160 adult participants randomized to receive a generative AI (n=81) or rules-based (n=79) version of a conversation-based DMHI. Self-report measures of the user relationship (client satisfaction, working alliance bond, and accuracy of empathic listening and reflection) and experience (engagement metrics, adverse events, and technical guardrail success) were collected. Descriptions and validation of technical guardrails for handling user inputs (eg, detecting potentially concerning language and off-topic responses) and model outputs (eg, not providing medical advice and not providing a diagnosis) are provided, along with examples to illustrate how they worked. Safety monitoring was conducted throughout the trial for adverse events, and the success of technical guardrails created for the generative arm was assessed post trial. Results: In general, the majority of measures of user relationship and experience appeared to be similar in both the generative and rules-based arms. The generative arm appeared to be more accurate at detecting and responding to user statements with empathy (98% accuracy vs 69%). There were no serious or device-related adverse events, and technical guardrails were shown to be 100% successful in posttrial review of generated statements. A majority of participants in both groups reported an increase in positive sentiment (62% and 66%) about AI at the end of the trial. Conclusions: This trial provides initial evidence that, with the right guardrails and process, generative AI can be successfully used in a digital mental health intervention (DMHI) while maintaining the user experience and relationship. It also provides an initial blueprint for approaches to technical and conversational guardrails that can be replicated to build a safe DMHI. Trial Registration: ClinicalTrials.gov NCT05948670; https://clinicaltrials.gov/study/NCT05948670
- 23 May 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27 (1) , e67365
Top Cited PapersOpen AccessSafety and User Experience of a Generative Artificial Intelligence Digital Mental Health Intervention: Exploratory Randomized Controlled Trial
Background: General awareness and exposure to generative artificial intelligence (AI) have increased recently. This transformative technology has the potential to create a more dynamic and engaging user experience in digital mental health interventions (DMHIs). However, if not appropriately used and controlled, it can introduce risks to users that may result in harm and erode trust. At the time of conducting this trial, there had not been a rigorous evaluation of an approach to safely implementing generative AI in a DMHI. Objective: This study aims to explore the user relationship, experience, safety, and technical guardrails of a DMHI using generative AI compared with a rules-based intervention. Methods: We conducted a 2-week exploratory randomized controlled trial (RCT) with 160 adult participants randomized to receive a generative AI (n=81) or rules-based (n=79) version of a conversation-based DMHI. Self-report measures of the user relationship (client satisfaction, working alliance bond, and accuracy of empathic listening and reflection) and experience (engagement metrics, adverse events, and technical guardrail success) were collected. Descriptions and validation of technical guardrails for handling user inputs (eg, detecting potentially concerning language and off-topic responses) and model outputs (eg, not providing medical advice and not providing a diagnosis) are provided, along with examples to illustrate how they worked. Safety monitoring was conducted throughout the trial for adverse events, and the success of technical guardrails created for the generative arm was assessed post trial. Results: In general, the majority of measures of user relationship and experience appeared to be similar in both the generative and rules-based arms. The generative arm appeared to be more accurate at detecting and responding to user statements with empathy (98% accuracy vs 69%). There were no serious or device-related adverse events, and technical guardrails were shown to be 100% successful in posttrial review of generated statements. A majority of participants in both groups reported an increase in positive sentiment (62% and 66%) about AI at the end of the trial. Conclusions: This trial provides initial evidence that, with the right guardrails and process, generative AI can be successfully used in a digital mental health intervention (DMHI) while maintaining the user experience and relationship. It also provides an initial blueprint for approaches to technical and conversational guardrails that can be replicated to build a safe DMHI. Trial Registration: ClinicalTrials.gov NCT05948670; https://clinicaltrials.gov/study/NCT05948670
- Open Access
- 27 January 2025
- Published by JMIR Publications Inc. in JMIR Mental Health
- Vol. 12 (1) , e64959
Establishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia: Two Exploratory Single-Arm Studies
Background: Evidence-based digital therapeutics represent a new treatment modality in mental health, potentially providing cost-efficient, accessible means of augmenting existing treatments for chronic mental illnesses. CT-155/BI 3972080 is a prescription digital therapeutic under development as an adjunct to standard of care treatments for patients 18 years of age and older with experiential negative symptoms (ENS) of schizophrenia. Individual components of CT-155/BI 3972080 are designed based on the underlying principles of face-to-face treatment. A positive therapeutic alliance between patients and health care providers is linked with improved clinical outcomes in mental health. Likewise, establishing a similar therapeutic alliance with a digital therapeutic (ie, digital working alliance [DWA]) may be important for engagement and treatment effectiveness of this modality. Objective: This study aimed to investigate the establishment and maintenance of a DWA between a beta version of CT-155/BI 3972080 (CT-155 beta) and adults with ENS of schizophrenia. Methods: Two multicenter, exploratory, single-arm studies (study 1: CT-155-C-001 and study 2: CT-155-C-002) enrolled adults with schizophrenia and ENS receiving stable antipsychotic medication (≥12 weeks). Participants had access to CT-155 beta and were presented with daily in-app activities during a 3-week orientation phase that included lessons designed to facilitate building of a DWA. In study 2, the 3-week orientation phase was followed by an abbreviated active 4-week phase. Digital literacy at baseline was evaluated using the Mobile Device Proficiency Questionnaire (MDPQ). The mobile Agnew Relationship Measure (mARM) was used to assess DWA establishment after 3 weeks in both studies, and after 7 weeks in study 2 to assess DWA maintenance. Participant safety, digital literacy, and correlations between negative symptom severity and DWA were assessed in both studies. Results: Of the enrolled participants, 94% (46/49) and 86% (43/50) completed studies 1 and 2, respectively. Most were male (study 1: 71%, 35/49; study 2: 80%, 40/50). The baseline digital literacy assessed through MDPQ score was comparable in both studies (study 1: mean 30.56, SD 8.06; study 2: mean 28.69, SD 8.31) indicating proficiency in mobile device use. After 3 weeks, mARM scores (study 1: mean 5.16, SD 0.8; study 2: mean 5.36, SD 1.06) indicated that a positive DWA was established in both studies. In study 2, the positive DWA established at week 3 was maintained at week 7 (mARM: mean 5.48, SD 0.97). There were no adverse events (AEs) in study 1, and 3 nonserious and nontreatment-related AEs in study 2. Conclusions: A positive DWA was established between participants and CT-155 beta within 3 weeks. The second 7-week study showed maintenance of the DWA to the end of the study. Results support the establishment and maintenance of a DWA between adults with ENS of schizophrenia and a beta version of CT-155/BI 3972080, a prescription digital therapeutic under development to target these symptoms. Trial Registration: Clinicaltrials.gov NCT05486312; https://clinicaltrials.gov/study/NCT05486312
- 27 January 2025
- Published by JMIR Publications Inc. in JMIR Mental Health
- Vol. 12 (1) , e64959
Open AccessEstablishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia: Two Exploratory Single-Arm Studies
Background: Evidence-based digital therapeutics represent a new treatment modality in mental health, potentially providing cost-efficient, accessible means of augmenting existing treatments for chronic mental illnesses. CT-155/BI 3972080 is a prescription digital therapeutic under development as an adjunct to standard of care treatments for patients 18 years of age and older with experiential negative symptoms (ENS) of schizophrenia. Individual components of CT-155/BI 3972080 are designed based on the underlying principles of face-to-face treatment. A positive therapeutic alliance between patients and health care providers is linked with improved clinical outcomes in mental health. Likewise, establishing a similar therapeutic alliance with a digital therapeutic (ie, digital working alliance [DWA]) may be important for engagement and treatment effectiveness of this modality. Objective: This study aimed to investigate the establishment and maintenance of a DWA between a beta version of CT-155/BI 3972080 (CT-155 beta) and adults with ENS of schizophrenia. Methods: Two multicenter, exploratory, single-arm studies (study 1: CT-155-C-001 and study 2: CT-155-C-002) enrolled adults with schizophrenia and ENS receiving stable antipsychotic medication (≥12 weeks). Participants had access to CT-155 beta and were presented with daily in-app activities during a 3-week orientation phase that included lessons designed to facilitate building of a DWA. In study 2, the 3-week orientation phase was followed by an abbreviated active 4-week phase. Digital literacy at baseline was evaluated using the Mobile Device Proficiency Questionnaire (MDPQ). The mobile Agnew Relationship Measure (mARM) was used to assess DWA establishment after 3 weeks in both studies, and after 7 weeks in study 2 to assess DWA maintenance. Participant safety, digital literacy, and correlations between negative symptom severity and DWA were assessed in both studies. Results: Of the enrolled participants, 94% (46/49) and 86% (43/50) completed studies 1 and 2, respectively. Most were male (study 1: 71%, 35/49; study 2: 80%, 40/50). The baseline digital literacy assessed through MDPQ score was comparable in both studies (study 1: mean 30.56, SD 8.06; study 2: mean 28.69, SD 8.31) indicating proficiency in mobile device use. After 3 weeks, mARM scores (study 1: mean 5.16, SD 0.8; study 2: mean 5.36, SD 1.06) indicated that a positive DWA was established in both studies. In study 2, the positive DWA established at week 3 was maintained at week 7 (mARM: mean 5.48, SD 0.97). There were no adverse events (AEs) in study 1, and 3 nonserious and nontreatment-related AEs in study 2. Conclusions: A positive DWA was established between participants and CT-155 beta within 3 weeks. The second 7-week study showed maintenance of the DWA to the end of the study. Results support the establishment and maintenance of a DWA between adults with ENS of schizophrenia and a beta version of CT-155/BI 3972080, a prescription digital therapeutic under development to target these symptoms. Trial Registration: Clinicaltrials.gov NCT05486312; https://clinicaltrials.gov/study/NCT05486312
- Open Access
- 15 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Safety and User Experience of a Generative Artificial Intelligence Digital Mental Health Intervention: Exploratory Randomized Controlled Trial (Preprint)
BACKGROUND General awareness and exposure to generative artificial intelligence (AI) have increased recently. This transformative technology has the potential to create a more dynamic and engaging user experience in digital mental health interventions (DMHIs). However, if not appropriately used and controlled, it can introduce risks to users that may result in harm and erode trust. At the time of conducting this trial, there had not been a rigorous evaluation of an approach to safely implementing generative AI in a DMHI. OBJECTIVE This study aims to explore the user relationship, experience, safety, and technical guardrails of a DMHI using generative AI compared with a rules-based intervention. METHODS We conducted a 2-week exploratory randomized controlled trial (RCT) with 160 adult participants randomized to receive a generative AI (n=81) or rules-based (n=79) version of a conversation-based DMHI. Self-report measures of the user relationship (client satisfaction, working alliance bond, and accuracy of empathic listening and reflection) and experience (engagement metrics, adverse events, and technical guardrail success) were collected. Descriptions and validation of technical guardrails for handling user inputs (eg, detecting potentially concerning language and off-topic responses) and model outputs (eg, not providing medical advice and not providing a diagnosis) are provided, along with examples to illustrate how they worked. Safety monitoring was conducted throughout the trial for adverse events, and the success of technical guardrails created for the generative arm was assessed post trial. RESULTS In general, the majority of measures of user relationship and experience appeared to be similar in both the generative and rules-based arms. The generative arm appeared to be more accurate at detecting and responding to user statements with empathy (98% accuracy vs 69%). There were no serious or device-related adverse events, and technical guardrails were shown to be 100% successful in posttrial review of generated statements. A majority of participants in both groups reported an increase in positive sentiment (62% and 66%) about AI at the end of the trial. CONCLUSIONS This trial provides initial evidence that, with the right guardrails and process, generative AI can be successfully used in a digital mental health intervention (DMHI) while maintaining the user experience and relationship. It also provides an initial blueprint for approaches to technical and conversational guardrails that can be replicated to build a safe DMHI. CLINICALTRIAL ClinicalTrials.gov NCT05948670; https://clinicaltrials.gov/study/NCT05948670
- 15 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessSafety and User Experience of a Generative Artificial Intelligence Digital Mental Health Intervention: Exploratory Randomized Controlled Trial (Preprint)
BACKGROUND General awareness and exposure to generative artificial intelligence (AI) have increased recently. This transformative technology has the potential to create a more dynamic and engaging user experience in digital mental health interventions (DMHIs). However, if not appropriately used and controlled, it can introduce risks to users that may result in harm and erode trust. At the time of conducting this trial, there had not been a rigorous evaluation of an approach to safely implementing generative AI in a DMHI. OBJECTIVE This study aims to explore the user relationship, experience, safety, and technical guardrails of a DMHI using generative AI compared with a rules-based intervention. METHODS We conducted a 2-week exploratory randomized controlled trial (RCT) with 160 adult participants randomized to receive a generative AI (n=81) or rules-based (n=79) version of a conversation-based DMHI. Self-report measures of the user relationship (client satisfaction, working alliance bond, and accuracy of empathic listening and reflection) and experience (engagement metrics, adverse events, and technical guardrail success) were collected. Descriptions and validation of technical guardrails for handling user inputs (eg, detecting potentially concerning language and off-topic responses) and model outputs (eg, not providing medical advice and not providing a diagnosis) are provided, along with examples to illustrate how they worked. Safety monitoring was conducted throughout the trial for adverse events, and the success of technical guardrails created for the generative arm was assessed post trial. RESULTS In general, the majority of measures of user relationship and experience appeared to be similar in both the generative and rules-based arms. The generative arm appeared to be more accurate at detecting and responding to user statements with empathy (98% accuracy vs 69%). There were no serious or device-related adverse events, and technical guardrails were shown to be 100% successful in posttrial review of generated statements. A majority of participants in both groups reported an increase in positive sentiment (62% and 66%) about AI at the end of the trial. CONCLUSIONS This trial provides initial evidence that, with the right guardrails and process, generative AI can be successfully used in a digital mental health intervention (DMHI) while maintaining the user experience and relationship. It also provides an initial blueprint for approaches to technical and conversational guardrails that can be replicated to build a safe DMHI. CLINICALTRIAL ClinicalTrials.gov NCT05948670; https://clinicaltrials.gov/study/NCT05948670
- Open Access
- 31 July 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Establishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia: Two Exploratory Single-Arm Studies (Preprint)
BACKGROUND Evidence-based digital therapeutics represent a new treatment modality in mental health, potentially providing cost-efficient, accessible means of augmenting existing treatments for chronic mental illnesses. CT-155/BI 3972080 is a prescription digital therapeutic under development as an adjunct to standard of care treatments for patients 18 years of age and older with experiential negative symptoms (ENS) of schizophrenia. Individual components of CT-155/BI 3972080 are designed based on the underlying principles of face-to-face treatment. A positive therapeutic alliance between patients and health care providers is linked with improved clinical outcomes in mental health. Likewise, establishing a similar therapeutic alliance with a digital therapeutic (ie, digital working alliance [DWA]) may be important for engagement and treatment effectiveness of this modality. OBJECTIVE This study aimed to investigate the establishment and maintenance of a DWA between a beta version of CT-155/BI 3972080 (CT-155 beta) and adults with ENS of schizophrenia. METHODS Two multicenter, exploratory, single-arm studies (study 1: CT-155-C-001 and study 2: CT-155-C-002) enrolled adults with schizophrenia and ENS receiving stable antipsychotic medication (≥12 weeks). Participants had access to CT-155 beta and were presented with daily in-app activities during a 3-week orientation phase that included lessons designed to facilitate building of a DWA. In study 2, the 3-week orientation phase was followed by an abbreviated active 4-week phase. Digital literacy at baseline was evaluated using the Mobile Device Proficiency Questionnaire (MDPQ). The mobile Agnew Relationship Measure (mARM) was used to assess DWA establishment after 3 weeks in both studies, and after 7 weeks in study 2 to assess DWA maintenance. Participant safety, digital literacy, and correlations between negative symptom severity and DWA were assessed in both studies. RESULTS Of the enrolled participants, 94% (46/49) and 86% (43/50) completed studies 1 and 2, respectively. Most were male (study 1: 71%, 35/49; study 2: 80%, 40/50). The baseline digital literacy assessed through MDPQ score was comparable in both studies (study 1: mean 30.56, SD 8.06; study 2: mean 28.69, SD 8.31) indicating proficiency in mobile device use. After 3 weeks, mARM scores (study 1: mean 5.16, SD 0.8; study 2: mean 5.36, SD 1.06) indicated that a positive DWA was established in both studies. In study 2, the positive DWA established at week 3 was maintained at week 7 (mARM: mean 5.48, SD 0.97). There were no adverse events (AEs) in study 1, and 3 nonserious and nontreatment-related AEs in study 2. CONCLUSIONS A positive DWA was established between participants and CT-155 beta within 3 weeks. The second 7-week study showed maintenance of the DWA to the end of the study. Results support the establishment and maintenance of a DWA between adults with ENS of schizophrenia and a beta version of CT-155/BI 3972080, a prescription digital therapeutic under development to target these symptoms. CLINICALTRIAL Clinicaltrials.gov NCT05486312; https://clinicaltrials.gov/study/NCT05486312
- 31 July 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEstablishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia: Two Exploratory Single-Arm Studies (Preprint)
BACKGROUND Evidence-based digital therapeutics represent a new treatment modality in mental health, potentially providing cost-efficient, accessible means of augmenting existing treatments for chronic mental illnesses. CT-155/BI 3972080 is a prescription digital therapeutic under development as an adjunct to standard of care treatments for patients 18 years of age and older with experiential negative symptoms (ENS) of schizophrenia. Individual components of CT-155/BI 3972080 are designed based on the underlying principles of face-to-face treatment. A positive therapeutic alliance between patients and health care providers is linked with improved clinical outcomes in mental health. Likewise, establishing a similar therapeutic alliance with a digital therapeutic (ie, digital working alliance [DWA]) may be important for engagement and treatment effectiveness of this modality. OBJECTIVE This study aimed to investigate the establishment and maintenance of a DWA between a beta version of CT-155/BI 3972080 (CT-155 beta) and adults with ENS of schizophrenia. METHODS Two multicenter, exploratory, single-arm studies (study 1: CT-155-C-001 and study 2: CT-155-C-002) enrolled adults with schizophrenia and ENS receiving stable antipsychotic medication (≥12 weeks). Participants had access to CT-155 beta and were presented with daily in-app activities during a 3-week orientation phase that included lessons designed to facilitate building of a DWA. In study 2, the 3-week orientation phase was followed by an abbreviated active 4-week phase. Digital literacy at baseline was evaluated using the Mobile Device Proficiency Questionnaire (MDPQ). The mobile Agnew Relationship Measure (mARM) was used to assess DWA establishment after 3 weeks in both studies, and after 7 weeks in study 2 to assess DWA maintenance. Participant safety, digital literacy, and correlations between negative symptom severity and DWA were assessed in both studies. RESULTS Of the enrolled participants, 94% (46/49) and 86% (43/50) completed studies 1 and 2, respectively. Most were male (study 1: 71%, 35/49; study 2: 80%, 40/50). The baseline digital literacy assessed through MDPQ score was comparable in both studies (study 1: mean 30.56, SD 8.06; study 2: mean 28.69, SD 8.31) indicating proficiency in mobile device use. After 3 weeks, mARM scores (study 1: mean 5.16, SD 0.8; study 2: mean 5.36, SD 1.06) indicated that a positive DWA was established in both studies. In study 2, the positive DWA established at week 3 was maintained at week 7 (mARM: mean 5.48, SD 0.97). There were no adverse events (AEs) in study 1, and 3 nonserious and nontreatment-related AEs in study 2. CONCLUSIONS A positive DWA was established between participants and CT-155 beta within 3 weeks. The second 7-week study showed maintenance of the DWA to the end of the study. Results support the establishment and maintenance of a DWA between adults with ENS of schizophrenia and a beta version of CT-155/BI 3972080, a prescription digital therapeutic under development to target these symptoms. CLINICALTRIAL Clinicaltrials.gov NCT05486312; https://clinicaltrials.gov/study/NCT05486312
- Open Access
- 28 March 2022
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 6 (3) , e29154
A Smartphone-Based Intervention as an Adjunct to Standard-of-Care Treatment for Schizophrenia: Randomized Controlled Trial
Background: Antipsychotic medications have limited benefits in schizophrenia, and cognitive behavioral therapy may be beneficial as an adjunct. There may be potential for implementing mobile cognitive behavioral therapy–based treatment for schizophrenia in addition to standard antipsychotic medications. Objective: This study aims to determine whether PEAR-004, a smartphone-based investigational digital therapeutic, improves the symptoms of an acute psychotic exacerbation of schizophrenia when it is added to standard treatments. Methods: This was a 12-week, multicenter, randomized, sham-controlled, rater-blinded, parallel group proof‑of‑concept study of 112 participants with moderate acute psychotic exacerbation in schizophrenia. This study was conducted in 6 clinical trial research sites in the United States from December 2018 to September 2019. The primary outcome, change in Positive and Negative Syndrome Scale (PANSS) from baseline to week 12 or the last available visit, was analyzed using the mixed-effects regression model for repeated measures, applied to an intent-to-treat sample. Results: The total PANSS scores slightly decreased from baseline over the study period in both groups; the treatment difference at day 85 between PEAR-004 and sham was 2.7 points, in favor of the sham (2-sided P=.09). The secondary scales found no benefit, except for transient improvement in depressive symptoms with PEAR-004. Application engagement was good, and patient and clinical investigator satisfaction was high. No safety concerns were observed. There was some evidence of study site heterogeneity for the onboarding processes and directions on PEAR-004 product use at baseline and throughout the study. However, these differences did not affect the efficacy results. Conclusions: In the largest-to-date randomized, sham-controlled study of a digital therapeutic in schizophrenia, PEAR-004 did not demonstrate an effect on the primary outcome—total PANSS scores—when compared with a nonspecific digital sham control. The secondary and exploratory results also did not demonstrate any notable benefits, except for possible temporary improvement in depressive symptoms. This study provided many useful scientific and operational insights that can be used in the further clinical development of PEAR-004 and other investigational digital therapeutics. Trial Registration: ClinicalTrials.gov NCT03751280; https://clinicaltrials.gov/ct2/show/NCT03751280
- 28 March 2022
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 6 (3) , e29154
Open AccessA Smartphone-Based Intervention as an Adjunct to Standard-of-Care Treatment for Schizophrenia: Randomized Controlled Trial
Background: Antipsychotic medications have limited benefits in schizophrenia, and cognitive behavioral therapy may be beneficial as an adjunct. There may be potential for implementing mobile cognitive behavioral therapy–based treatment for schizophrenia in addition to standard antipsychotic medications. Objective: This study aims to determine whether PEAR-004, a smartphone-based investigational digital therapeutic, improves the symptoms of an acute psychotic exacerbation of schizophrenia when it is added to standard treatments. Methods: This was a 12-week, multicenter, randomized, sham-controlled, rater-blinded, parallel group proof‑of‑concept study of 112 participants with moderate acute psychotic exacerbation in schizophrenia. This study was conducted in 6 clinical trial research sites in the United States from December 2018 to September 2019. The primary outcome, change in Positive and Negative Syndrome Scale (PANSS) from baseline to week 12 or the last available visit, was analyzed using the mixed-effects regression model for repeated measures, applied to an intent-to-treat sample. Results: The total PANSS scores slightly decreased from baseline over the study period in both groups; the treatment difference at day 85 between PEAR-004 and sham was 2.7 points, in favor of the sham (2-sided P=.09). The secondary scales found no benefit, except for transient improvement in depressive symptoms with PEAR-004. Application engagement was good, and patient and clinical investigator satisfaction was high. No safety concerns were observed. There was some evidence of study site heterogeneity for the onboarding processes and directions on PEAR-004 product use at baseline and throughout the study. However, these differences did not affect the efficacy results. Conclusions: In the largest-to-date randomized, sham-controlled study of a digital therapeutic in schizophrenia, PEAR-004 did not demonstrate an effect on the primary outcome—total PANSS scores—when compared with a nonspecific digital sham control. The secondary and exploratory results also did not demonstrate any notable benefits, except for possible temporary improvement in depressive symptoms. This study provided many useful scientific and operational insights that can be used in the further clinical development of PEAR-004 and other investigational digital therapeutics. Trial Registration: ClinicalTrials.gov NCT03751280; https://clinicaltrials.gov/ct2/show/NCT03751280
- Open Access
- 28 March 2021
- Published by JMIR Publications Inc. in JMIR Preprints
A Smartphone-Based Intervention as an Adjunct to Standard-of-Care Treatment for Schizophrenia: Randomized Controlled Trial (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Antipsychotic medications have limited benefits in schizophrenia, and cognitive behavioral therapy may be beneficial as an adjunct. There may be potential for implementing mobile cognitive behavioral therapy–based treatment for schizophrenia in addition to standard antipsychotic medications. Objective: This study aims to determine whether PEAR-004, a smartphone-based investigational digital therapeutic, improves the symptoms of an acute psychotic exacerbation of schizophrenia when it is added to standard treatments. Methods: This was a 12-week, multicenter, randomized, sham-controlled, rater-blinded, parallel group proof‑of‑concept study of 112 participants with moderate acute psychotic exacerbation in schizophrenia. This study was conducted in 6 clinical trial research sites in the United States from December 2018 to September 2019. The primary outcome, change in Positive and Negative Syndrome Scale (PANSS) from baseline to week 12 or the last available visit, was analyzed using the mixed-effects regression model for repeated measures, applied to an intent-to-treat sample. Results: The total PANSS scores slightly decreased from baseline over the study period in both groups; the treatment difference at day 85 between PEAR-004 and sham was 2.7 points, in favor of the sham (2-sided P=.09). The secondary scales found no benefit, except for transient improvement in depressive symptoms with PEAR-004. Application engagement was good, and patient and clinical investigator satisfaction was high. No safety concerns were observed. There was some evidence of study site heterogeneity for the onboarding processes and directions on PEAR-004 product use at baseline and throughout the study. However, these differences did not affect the efficacy results. Conclusions: In the largest-to-date randomized, sham-controlled study of a digital therapeutic in schizophrenia, PEAR-004 did not demonstrate an effect on the primary outcome—total PANSS scores—when compared with a nonspecific digital sham control. The secondary and exploratory results also did not demonstrate any notable benefits, except for possible temporary improvement in depressive symptoms. This study provided many useful scientific and operational insights that can be used in the further clinical development of PEAR-004 and other investigational digital therapeutics. Trial Registration: ClinicalTrials.gov NCT03751280; https://clinicaltrials.gov/ct2/show/NCT03751280
- 28 March 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessA Smartphone-Based Intervention as an Adjunct to Standard-of-Care Treatment for Schizophrenia: Randomized Controlled Trial (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Antipsychotic medications have limited benefits in schizophrenia, and cognitive behavioral therapy may be beneficial as an adjunct. There may be potential for implementing mobile cognitive behavioral therapy–based treatment for schizophrenia in addition to standard antipsychotic medications. Objective: This study aims to determine whether PEAR-004, a smartphone-based investigational digital therapeutic, improves the symptoms of an acute psychotic exacerbation of schizophrenia when it is added to standard treatments. Methods: This was a 12-week, multicenter, randomized, sham-controlled, rater-blinded, parallel group proof‑of‑concept study of 112 participants with moderate acute psychotic exacerbation in schizophrenia. This study was conducted in 6 clinical trial research sites in the United States from December 2018 to September 2019. The primary outcome, change in Positive and Negative Syndrome Scale (PANSS) from baseline to week 12 or the last available visit, was analyzed using the mixed-effects regression model for repeated measures, applied to an intent-to-treat sample. Results: The total PANSS scores slightly decreased from baseline over the study period in both groups; the treatment difference at day 85 between PEAR-004 and sham was 2.7 points, in favor of the sham (2-sided P=.09). The secondary scales found no benefit, except for transient improvement in depressive symptoms with PEAR-004. Application engagement was good, and patient and clinical investigator satisfaction was high. No safety concerns were observed. There was some evidence of study site heterogeneity for the onboarding processes and directions on PEAR-004 product use at baseline and throughout the study. However, these differences did not affect the efficacy results. Conclusions: In the largest-to-date randomized, sham-controlled study of a digital therapeutic in schizophrenia, PEAR-004 did not demonstrate an effect on the primary outcome—total PANSS scores—when compared with a nonspecific digital sham control. The secondary and exploratory results also did not demonstrate any notable benefits, except for possible temporary improvement in depressive symptoms. This study provided many useful scientific and operational insights that can be used in the further clinical development of PEAR-004 and other investigational digital therapeutics. Trial Registration: ClinicalTrials.gov NCT03751280; https://clinicaltrials.gov/ct2/show/NCT03751280
- 1 August 2018
- Published by Elsevier in Journal of Affective Disorders
- Vol. 235, 316-322
Parsing positivity in the bipolar spectrum: The effect of context on social decision-making
- 1 August 2018
- Published by Elsevier in Journal of Affective Disorders
- Vol. 235, 316-322
Parsing positivity in the bipolar spectrum: The effect of context on social decision-making